Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q4 FY25 results · Jan–Mar 2025
Bliss GVS Pharma reported revenue from operations of ₹197.99 crore (down 0.1% from Q4 FY24) and net profit of ₹16.65 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 197.99 | 198.13 | −0.1% | 210.42 | −5.9% |
| Other income | 12.07 | 5.60 | +115.5% | 15.27 | −20.9% |
| Total income | 210.05 | 203.73 | +3.1% | 225.68 | −6.9% |
| Profit before tax | 23.44 | (3.95) | Turned profit | 36.42 | −35.6% |
| Net profit for the period | 16.65 | (4.91) | Turned profit | 25.80 | −35.5% |
| Attributable to shareholders of the company | 15.54 | (9.15) | Turned profit | 23.80 | −34.7% |
| EPS, basic (₹) | 1.47 | (0.88) | Turned profit | 2.27 | −35.2% |
| Net margin (%) | 8.4 | -2.5 | 12.3 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 156.00 | 163.82 | −4.8% | 179.59 | −13.1% |
| Other income | 9.36 | 8.46 | +10.6% | 11.66 | −19.7% |
| Total income | 165.36 | 172.28 | −4.0% | 191.25 | −13.5% |
| Profit before tax | 14.36 | (15.23) | Turned profit | 29.77 | −51.8% |
| Net profit for the period | 11.45 | (11.46) | Turned profit | 21.05 | −45.6% |
| EPS, basic (₹) | 1.08 | (1.11) | Turned profit | 2.00 | −46.0% |
| Net margin (%) | 7.3 | -7.0 | 11.7 |
Consolidated
- Filed with BSE
- 12 May 2025, 22:48 IST
- Board meeting
- 12 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 May 2025, 22:48 IST
- Board meeting
- 12 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE